Content about Thrombocytopenia

February 21, 2013

The Food and Drug Administration has approved a new vial size for a drug made by CSL Behring to treat a bleeding disorder and an immune disorder, the company said.

KING OF PRUSSIA, Pa. — The Food and Drug Administration has approved a new vial size for a drug made by CSL Behring to treat a bleeding disorder and an immune disorder, the company said Thursday.

November 19, 2012

The Food and Drug Administration has approved a drug for a condition that can complicate treatment for hepatitis C.

LONDON — The Food and Drug Administration has approved a drug for a condition that can complicate treatment for hepatitis C.

GlaxoSmithKline said Monday that the FDA had approved Promacta (eltrombopag) for treating low blood-platelet counts, also known as thrombocytopenia, to allow patients with hepatitis C to undergo and maintain interferon-based therapy. The drug already had FDA approval to treat chronic immune thrombocytopenia. 

December 7, 2011

Prescribers, patients and specialty care centers no longer will be required to enroll in safety monitoring programs for two drugs used to treat low platelet counts, following changes to their risk evaluation and mitigation strategies.

SILVER SPRING, Md. — Prescribers, patients and specialty care centers no longer will be required to enroll in safety monitoring programs for two drugs used to treat low platelet counts, following changes to their risk evaluation and mitigation strategies.

February 28, 2011

The Food and Drug Administration has approved a GlaxoSmithKline drug for a rare blood disorder, GSK said Friday.

PHILADELPHIA — The Food and Drug Administration has approved a GlaxoSmithKline drug for a rare blood disorder, GSK said Friday.

The drug maker announced the approval of Promacta (eltrombopag) for chronic immune thrombocytopenic purpura, or ITP, in patients who have not responded adequately to other therapies. Chronic ITP results in increased destruction of inadequate production of platelets in the blood, creating an increased risk of bruising and bleeding.

The FDA granted Promacta orphan drug designation in May 2008 and accelerated approval in November 2008.

December 6, 2010

A drug made by Amgen maintained blood platelet counts in patients with an autoimmune bleeding disorder, according to results of a five-year study released Sunday.

ORLANDO, Fla. — A drug made by Amgen maintained blood platelet counts in patients with an autoimmune bleeding disorder, according to results of a five-year study released Sunday.